Epalrestat-RM-13
Epalrestat (EPA), an FDA-approved drug, is a potent inhibitor of aldose reductase and exhibits anticancer activity with poor pharmacokinetic properties. Prodrugs RM-13 and RM-28 are esterase-responsive turn-on fluorogenic prodrugs for the sustained release of EPA to cancer cells
General
Type : Not AlphaBeta Hydrolase target, Pro-Drug, Drug, Fluorescent Probe, Coumarin, Chromen, Thiazolidine, Sulfur Compound
Chemical_Nomenclature : 7-methyl pivalate coumarinyl-2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid
Canonical SMILES : C1=C(C=C2C(=C1)C=C(C(O2)=O)COC(CN3C(SC(C3=O)=CC(=CC4=CC=CC=C4)C)=S)=O)OCOC(C(C)(C)C)=O
InChI : InChI=1S\/C31H29NO8S2\/c1-19(12-20-8-6-5-7-9-20)13-25-27(34)32(30(41)42-25)16-26(33)37-17-22-14-21-10-11-23(15-24(21)40-28(22)35)38-18-39-29(36)31(2,3)4\/h5-15H,16-18H2,1-4H3
InChIKey : RLEROCNAUHOFSY-UHFFFAOYSA-N
Other name(s) :
Target
Structures : No structure
Families : No family
References (1)
| Title : Esterase-Responsive Fluorogenic Prodrugs of Aldose Reductase Inhibitor Epalrestat: An Innovative Strategy toward Enhanced Anticancer Activity - Misra_2024_ACS.Appl.Bio.Mater__ |
| Author(s) : Misra R , Barman P , Bhabak KP |
| Ref : ACS Appl Bio Mater , : , 2024 |
| Abstract : |
| PubMedSearch : Misra_2024_ACS.Appl.Bio.Mater__ |
| PubMedID: 39146213 |